CAS Number: 951395-08-7
Therapeutic Category
Cardiovascular
API Technology
Synthetic
Dose Form
Oral Solid/Capsules
Dr Reddy's Development Status
Available
Available Regulatory Filing
Brazil DMF
Tafamidis Meglumine is a drug used to treat transthyretin (TTR) amyloidosis, a rare genetic disease characterized by the buildup of abnormal proteins in various tissues and organs, including the heart, peripheral nerves, and eyes.
The mechanism of action of Tafamidis Meglumine is based on its ability to stabilize the TTR tetramer, which is the native form of the protein. Tafamidis Meglumine binds to the TTR protein and prevents it from undergoing a conformational change that would normally lead to its aggregation and formation of amyloid fibrils. By stabilizing the TTR tetramer, Tafamidis Meglumine slows down the progression of TTR amyloidosis and helps to preserve the function of affected tissues and organs.
In addition, Tafamidis Meglumine has been shown to have an anti-inflammatory effect, which may also contribute to its therapeutic effects in TTR amyloidosis.
Tafamidis Meglumine is a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a type of heart disease caused by buildup of amyloid deposits in the heart. It works by stabilizing the transthyretin protein, which helps to prevent the formation of amyloid deposits and slow the progression of heart damage.
Tafamidis Meglumine is indicated for the treatment of transthyretin amyloid cardiomyopathy in adult patients with stage F2 or F3 cardiac symptoms (based on the New York Heart Association [NYHA] functional classification).
It is important to note that Tafamidis Meglumine is not a cure for transthyretin amyloid cardiomyopathy, but it can help to slow the progression of the disease and improve symptoms in some patients.
Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。
Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 氯苯唑酸葡甲胺 API是研发,知识产权和监管方面广泛专业知识的结果。
帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。
本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。
Sign-up for our email service to get Market and Product insights and updates right to your digital doorstep
The categories of personal information collected in this form include name, company, and contact information etc. The personal information collected will be used for exploratory discussions on contract manufacturing, marketing and to perform research and analytics and others. For more information about the categories of personal information collected by Dr.Reddy's and the purposes for which Dr.Reddy's uses personal information, visit https://api.drreddys.com/privacy-policy.
本目錄中的任何信息(包括對任何產品或服務的任何引用)均不構成銷售要約,或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是,只要存在此類監管豁免,就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估,並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途,但可用於第 107A 節。